Issue 12, 2021

Mass spectrometry reveals potential of β-lactams as SARS-CoV-2 Mpro inhibitors

Abstract

The main viral protease (Mpro) of SARS-CoV-2 is a nucleophilic cysteine hydrolase and a current target for anti-viral chemotherapy. We describe a high-throughput solid phase extraction coupled to mass spectrometry Mpro assay. The results reveal some β-lactams, including penicillin esters, are active site reacting Mpro inhibitors, thus highlighting the potential of acylating agents for Mpro inhibition.

Graphical abstract: Mass spectrometry reveals potential of β-lactams as SARS-CoV-2 Mpro inhibitors

Supplementary files

Article information

Article type
Communication
Submitted
14 Oct 2020
Accepted
23 Nov 2020
First published
19 Jan 2021
This article is Open Access
Creative Commons BY license

Chem. Commun., 2021,57, 1430-1433

Mass spectrometry reveals potential of β-lactams as SARS-CoV-2 Mpro inhibitors

T. R. Malla, A. Tumber, T. John, L. Brewitz, C. Strain-Damerell, C. D. Owen, P. Lukacik, H. T. H. Chan, P. Maheswaran, E. Salah, F. Duarte, H. Yang, Z. Rao, M. A. Walsh and C. J. Schofield, Chem. Commun., 2021, 57, 1430 DOI: 10.1039/D0CC06870E

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements